News & Publications

Conference

This ASCO-GU conference abstract describes the early clinical development of LAVA-1207, a PSMA-directed bispecific gamma-delta T cell engager evaluated in metastatic castration-resistant prostate cancer.

Conference

This ASH conference abstract reports early clinical and pharmacodynamic observations for LAVA-051, a CD1d-directed bispecific gamma-delta T cell engager studied in relapsed or refractory hematological malignancies.

Publication

This publication explores how lenalidomide may enhance the activity of CD1d-Vδ2 bispecific antibody-engaged Vγ9Vδ2 T cells. The work adds to the scientific foundation for combining unconventional T cell engagement with established treatment modalities.

Publication

This publication describes a 5T4-directed Vδ2 bispecific T cell engager designed to recruit Vγ9Vδ2 T cells against solid tumor cells. The work adds to the scientific foundation for using unconventional T cells to support tumor-selective immune responses.

Publication

This study describes a PD-L1-directed bispecific Vδ2 T cell engager designed to combine tumor-cell targeting with immune checkpoint biology.

Publication

This publication investigates a VHH-based PSMA-Vδ2 bispecific T cell engager for prostate cancer. The work supports the broader rationale for redirecting Vγ9Vδ2 T cells toward tumor-associated antigens.

Publication

This study explores Vδ2 T cell engagers designed to support antitumor immunity while promoting expansion of Vγ9Vδ2 T cells.

Publication

This publication evaluates a bispecific γδ T cell engager targeting EGFR-expressing tumors. The work adds to the scientific foundation and illustrates the apparent safety of redirecting Vγ9Vδ2 T cells toward a broadly expressed tumor-associated antigen.

Publication

This publication describes a bispecific T cell engager designed to simultaneously recruit two unconventional T cell populations, type 1 NKT cells and Vγ9Vδ2 T cells, to target CD1d-expressing hematological malignancies.

Review

This review summarizes past, present and future directions for γδ T cell-based cancer immunotherapy. It provides context for why unconventional T cells are being explored as a distinct and promising immune-cell compartment.

Publication

This study investigates a bispecific antibody approach designed to counter CD40-mediated survival signaling while promoting Vγ9Vδ2 T cell-mediated antitumor responses in human B-cell malignancies.

Publication

This foundational study describes a single-domain bispecific antibody approach targeting CD1d and the type 1 NKT T cell receptor. The work adds to the scientific basis for exploring unconventional T cell:cell biology in cancer immunotherapy.